BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014;10:365-73. [PMID: 24614588 DOI: 10.1038/nrrheum.2014.33] [Cited by in Crossref: 227] [Cited by in F6Publishing: 208] [Article Influence: 32.4] [Reference Citation Analysis]
Number Citing Articles
1 Wallace DJ, Isenberg DA, Morand EF, Vazquez-Mateo C, Kao AH, Aydemir A, Pudota K, Ona V, Aranow C, Merrill JT. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford) 2021;60:5379-89. [PMID: 33547784 DOI: 10.1093/rheumatology/keab115] [Reference Citation Analysis]
2 Raymond WD, Eilertsen GØ, Nossent J. Principal component analysis reveals disconnect between regulatory cytokines and disease activity in Systemic Lupus Erythematosus. Cytokine 2019;114:67-73. [PMID: 30551949 DOI: 10.1016/j.cyto.2018.10.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
3 Kaegi C, Steiner UC, Wuest B, Crowley C, Boyman O. Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. Front Immunol 2020;11:433. [PMID: 32265917 DOI: 10.3389/fimmu.2020.00433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
4 Chasset F, de Masson A, Le Buanec H, Xhaard A, de Fontbrune FS, Robin M, Rybojad M, Parquet N, Brignier AC, Coman T, Bengoufa D, Bergeron A, Peffault de Latour R, Bagot M, Bensussan A, Socié G, Bouaziz JD. APRIL levels are associated with disease activity in human chronic graft-versus-host disease. Haematologica 2016;101:e312-5. [PMID: 26992945 DOI: 10.3324/haematol.2016.145409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
5 Patra MC, Achek A, Kim GY, Panneerselvam S, Shin HJ, Baek WY, Lee WH, Sung J, Jeong U, Cho EY, Kim W, Kim E, Suh CH, Choi S. A Novel Small-Molecule Inhibitor of Endosomal TLRs Reduces Inflammation and Alleviates Autoimmune Disease Symptoms in Murine Models. Cells 2020;9:E1648. [PMID: 32660060 DOI: 10.3390/cells9071648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ban T, Sato GR, Tamura T. Regulation and role of the transcription factor IRF5 in innate immune responses and systemic lupus erythematosus. Int Immunol 2018;30:529-36. [PMID: 29860420 DOI: 10.1093/intimm/dxy032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
7 Engels EA, Jennings LW, Everly MJ, Landgren O, Murata K, Yanik EL, Pfeiffer RM, Onaca N, Klintmalm GB. Donor-specific Antibodies, Immunoglobulin-free Light Chains, and BAFF Levels in Relation to Risk of Late-onset PTLD in Liver Recipients. Transplant Direct 2018;4:e353. [PMID: 30123826 DOI: 10.1097/TXD.0000000000000792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
8 Tay J, Costanzi A, Basello K, Piuri G, Ferrazzi E, Speciani AF, Lees CC. Maternal Serum B Cell activating factor in hypertensive and normotensive pregnancies. Pregnancy Hypertens 2018;13:58-61. [PMID: 30177072 DOI: 10.1016/j.preghy.2018.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Gies V, Schickel JN, Jung S, Joublin A, Glauzy S, Knapp AM, Soley A, Poindron V, Guffroy A, Choi JY, Gottenberg JE, Anolik JH, Martin T, Soulas-Sprauel P, Meffre E, Korganow AS. Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus. JCI Insight 2018;3:96795. [PMID: 29515028 DOI: 10.1172/jci.insight.96795] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
10 Zhang Y, Li J, Zhang YM, Zhang XM, Tao J. Effect of TACI signaling on humoral immunity and autoimmune diseases. J Immunol Res 2015;2015:247426. [PMID: 25866827 DOI: 10.1155/2015/247426] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
11 OʼLeary JG, Samaniego M, Barrio MC, Potena L, Zeevi A, Djamali A, Cozzi E. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation 2016;100:39-53. [PMID: 26680372 DOI: 10.1097/TP.0000000000000869] [Cited by in Crossref: 73] [Cited by in F6Publishing: 21] [Article Influence: 14.6] [Reference Citation Analysis]
12 Liu H, Pan C, Song W, Liu D, Li Z, Zheng L. Novel strategies for immuno-oncology breakthroughs with cell therapy. Biomark Res 2021;9:62. [PMID: 34332618 DOI: 10.1186/s40364-021-00316-6] [Reference Citation Analysis]
13 van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Rheumatology (Oxford) 2020;59:281-91. [PMID: 31302695 DOI: 10.1093/rheumatology/kez279] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
14 Figgett WA, Vincent FB, Saulep-Easton D, Mackay F. Roles of ligands from the TNF superfamily in B cell development, function, and regulation. Semin Immunol 2014;26:191-202. [PMID: 24996229 DOI: 10.1016/j.smim.2014.06.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
15 Squatrito D, Emmi G, Silvestri E, Ciucciarelli L, D'Elios MM, Prisco D, Emmi L. Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside. Auto Immun Highlights 2014;5:33-45. [PMID: 26000154 DOI: 10.1007/s13317-014-0058-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
16 Hoffmann FS, Kuhn PH, Laurent SA, Hauck SM, Berer K, Wendlinger SA, Krumbholz M, Khademi M, Olsson T, Dreyling M, Pfister HW, Alexander T, Hiepe F, Kümpfel T, Crawford HC, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E. The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol 2015;194:542-52. [PMID: 25505277 DOI: 10.4049/jimmunol.1402070] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
17 Papagiannuli E, Rhodes B, Wallace GR, Gordon C, Murray PI, Denniston AK. Systemic lupus erythematosus: An update for ophthalmologists. Surv Ophthalmol 2016;61:65-82. [PMID: 26197421 DOI: 10.1016/j.survophthal.2015.06.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
18 Ogawa E, Wei MT, Nguyen MH. Hepatitis B Virus Reactivation Potentiated by Biologics. Infect Dis Clin North Am 2020;34:341-58. [PMID: 32334985 DOI: 10.1016/j.idc.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Pinna RA, Dos Santos AC, Perce-da-Silva DS, da Silva LA, da Silva RNR, Alves MR, Santos F, de Oliveira Ferreira J, Lima-Junior JC, Villa-Verde DM, De Luca PM, Carvalho-Pinto CE, Banic DM. Correlation of APRIL with production of inflammatory cytokines during acute malaria in the Brazilian Amazon. Immun Inflamm Dis 2018;6:207-20. [PMID: 29314720 DOI: 10.1002/iid3.208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
20 Tayel MY, Nazir A, Abdelhamid IM, Helmy MAS, Zaki NE, Elsharkawy NS, Fayad AI. TNF-α -308 G>A and IL10 -1082A>G polymorphisms as potential risk factors for lymphoproliferative disorders in autoimmune rheumatic diseases. Egypt J Med Hum Genet 2020;21. [DOI: 10.1186/s43042-019-0043-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Meyer-Bahlburg A, Dijkstra D. [Basophilic granulocytes and autoimmune diseases. Can basophilic granulocytes modulate B-cell functions in systemic lupus erythematosus?]. Z Rheumatol 2016;75:245-52. [PMID: 26820721 DOI: 10.1007/s00393-015-0039-1] [Reference Citation Analysis]
22 Liu X, Jiao Y, Cui B, Gao X, Xu J, Zhao Y. The potential protective role of hepatitis B virus infection in pristane-induced lupus in mice. Lupus 2016;25:1180-9. [PMID: 27125291 DOI: 10.1177/0961203316631637] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
23 Howe HS, Thong BYH, Kong KO, Chng HH, Lian TY, Chia FL, Tay KSS, Lau TC, Law WG, Koh ET, Leung BP. Associations of B cell-activating factor (BAFF) and anti-BAFF autoantibodies with disease activity in multi-ethnic Asian systemic lupus erythematosus patients in Singapore. Clin Exp Immunol 2017;189:298-303. [PMID: 28388832 DOI: 10.1111/cei.12975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
24 Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, Struyf S. Local Cytokine Expression Profiling in Patients with Specific Autoimmune Uveitic Entities. Ocul Immunol Inflamm 2020;28:453-62. [PMID: 31161935 DOI: 10.1080/09273948.2019.1604974] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
25 Goilav B, Putterman C, Rubinstein TB. Biomarkers for kidney involvement in pediatric lupus. Biomark Med 2015;9:529-43. [PMID: 26079958 DOI: 10.2217/bmm.15.25] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
26 Fairfax KA, Tsantikos E, Figgett WA, Vincent FB, Quah PS, Lepage M, Hibbs ML, Mackay F. BAFF-driven autoimmunity requires CD19 expression. Journal of Autoimmunity 2015;62:1-10. [DOI: 10.1016/j.jaut.2015.06.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
27 Yang SH, Gao CY, Li L, Chang C, Leung PSC, Gershwin ME, Lian ZX. The molecular basis of immune regulation in autoimmunity. Clin Sci (Lond) 2018;132:43-67. [PMID: 29305419 DOI: 10.1042/CS20171154] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
28 Flynn JK, Dankers W, Morand EF. Could GILZ Be the Answer to Glucocorticoid Toxicity in Lupus? Front Immunol 2019;10:1684. [PMID: 31379872 DOI: 10.3389/fimmu.2019.01684] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
29 Noack M, Miossec P. Importance of lymphocyte-stromal cell interactions in autoimmune and inflammatory rheumatic diseases. Nat Rev Rheumatol 2021;17:550-64. [PMID: 34345021 DOI: 10.1038/s41584-021-00665-4] [Reference Citation Analysis]
30 Zou Z, Du D, Miao Y, Yang Y, Xie Y, Li Z, Zhou L, Zhang L, Zhou P, Jiang F. TJ-M2010-5, a novel MyD88 inhibitor, corrects R848-induced lupus-like immune disorders of B cells in vitro. Int Immunopharmacol 2020;85:106648. [PMID: 32504998 DOI: 10.1016/j.intimp.2020.106648] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Mahmoudi M, Aslani S, Meguro A, Akhtari M, Fatahi Y, Mizuki N, Shahram F. A comprehensive overview on the genetics of Behçet's disease. Int Rev Immunol 2020;:1-64. [PMID: 33258398 DOI: 10.1080/08830185.2020.1851372] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Timmermans WM, van Laar JA, van Hagen PM, van Zelm MC. Immunopathogenesis of granulomas in chronic autoinflammatory diseases. Clin Transl Immunology 2016;5:e118. [PMID: 28090320 DOI: 10.1038/cti.2016.75] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
33 Valor L, López-Longo FJ. [Modulating the survival and maturation system of B lymphocytes: Current and future new therapeutic strategies in systemic lupus erythematosus]. Med Clin (Barc) 2015;145:206-10. [PMID: 25433780 DOI: 10.1016/j.medcli.2014.08.008] [Reference Citation Analysis]
34 Albani S, Wedderburn LR, Prakken B. Adaptive Immunity and Autoimmunity. Textbook of Pediatric Rheumatology. Elsevier; 2016. pp. 33-42.e3. [DOI: 10.1016/b978-0-323-24145-8.00004-1] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
35 MacDonald KP, Blazar BR, Hill GR. Cytokine mediators of chronic graft-versus-host disease. J Clin Invest. 2017;127:2452-2463. [PMID: 28665299 DOI: 10.1172/jci90593] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 12.5] [Reference Citation Analysis]
36 Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Hoi AY, Harris J, Mackay F, Morand EF. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus. Clin Transl Immunology 2019;8:e01047. [PMID: 31024730 DOI: 10.1002/cti2.1047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
37 Nie Y, Zhao L, Zhang X. B Cell Aberrance in Lupus: the Ringleader and the Solution. Clin Rev Allergy Immunol 2021. [PMID: 33534064 DOI: 10.1007/s12016-020-08820-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Shin W, Lee HT, Lim H, Lee SH, Son JY, Lee JU, Yoo KY, Ryu SE, Rhie J, Lee JY, Heo YS. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus. Nat Commun 2018;9:1200. [PMID: 29572471 DOI: 10.1038/s41467-018-03620-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
39 Giordano D, Draves KE, Young LB, Roe K, Bryan MA, Dresch C, Richner JM, Diamond MS, Gale M Jr, Clark EA. Protection of mice deficient in mature B cells from West Nile virus infection by passive and active immunization. PLoS Pathog 2017;13:e1006743. [PMID: 29176765 DOI: 10.1371/journal.ppat.1006743] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
40 Porsch F, Binder CJ. Impact of B-Cell–Targeted Therapies on Cardiovascular Disease. ATVB 2019;39:1705-14. [DOI: 10.1161/atvbaha.119.311996] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
41 Nakayama Y, Kosek J, Capone L, Hur EM, Schafer PH, Ringheim GE. Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity. J Immunol 2017;199:2388-407. [PMID: 28848067 DOI: 10.4049/jimmunol.1601725] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
42 Hui-Yuen JS, Nguyen SC, Askanase AD. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus. Lupus 2016;25:1086-96. [PMID: 27497253 DOI: 10.1177/0961203316652491] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
43 Liang Y, Tsoi LC, Xing X, Beamer MA, Swindell WR, Sarkar MK, Berthier CC, Stuart PE, Harms PW, Nair RP, Elder JT, Voorhees JJ, Kahlenberg JM, Gudjonsson JE. A gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases. Nat Immunol. 2017;18:152-160. [PMID: 27992404 DOI: 10.1038/ni.3643] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 10.8] [Reference Citation Analysis]
44 Sakai J, Akkoyunlu M. The Role of BAFF System Molecules in Host Response to Pathogens. Clin Microbiol Rev 2017;30:991-1014. [PMID: 28855265 DOI: 10.1128/CMR.00046-17] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 8.8] [Reference Citation Analysis]
45 Yang B, Zhao M, Wu H, Lu Q. A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target. Front Immunol 2020;11:539797. [PMID: 33123125 DOI: 10.3389/fimmu.2020.539797] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Kannel K, Alnek K, Vahter L, Gross-Paju K, Uibo R, Kisand KV. Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome. PLoS One 2015;10:e0143393. [PMID: 26600308 DOI: 10.1371/journal.pone.0143393] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
47 Engh JA, Ueland T, Agartz I, Andreou D, Aukrust P, Boye B, Bøen E, Drange OK, Elvsåshagen T, Hope S, Høegh MC, Joa I, Johnsen E, Kroken RA, Lagerberg TV, Lekva T, Malt UF, Melle I, Morken G, Nærland T, Steen VM, Wedervang-Resell K, Weibell MA, Westlye LT, Djurovic S, Steen NE, Andreassen OA. Plasma Levels of the Cytokines B Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) in Schizophrenia, Bipolar, and Major Depressive Disorder: A Cross Sectional, Multisite Study. Schizophr Bull 2021:sbab106. [PMID: 34499169 DOI: 10.1093/schbul/sbab106] [Reference Citation Analysis]
48 Martín‐penagos L, Benito‐hernández A, San Segundo D, Sango C, Azueta A, Gómez‐román J, Fernández‐fresnedo G, López‐hoyos M, Ruiz JC, Rodrigo E. A proliferation‐inducing ligand increase precedes IgA nephropathy recurrence in kidney transplant recipients. Clin Transplant 2019;33:e13502. [DOI: 10.1111/ctr.13502] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
49 Tran NL, Schneider P, Santiago-raber M. TACI-dependent APRIL signaling maintains autoreactive B cells in a mouse model of systemic lupus erythematosus. Eur J Immunol 2017;47:713-23. [DOI: 10.1002/eji.201646630] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
50 Sentís A, Diekmann F, Llobell A, de Moner N, Espinosa G, Yagüe J, Campistol JM, Mirapeix E, Juan M. Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology. Immunobiology 2017;222:620-30. [PMID: 27986304 DOI: 10.1016/j.imbio.2016.11.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
51 Salazar-Camarena DC, Ortíz-Lazareno P, Marín-Rosales M, Cruz A, Muñoz-Valle F, Tapia-Llanos R, Orozco-Barocio G, Machado-Contreras R, Palafox-Sánchez CA. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus. Cytokine 2019;114:115-27. [PMID: 30467093 DOI: 10.1016/j.cyto.2018.11.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
52 Aguirre-Valencia D, Ríos-Serna LJ, Posso-Osorio I, Naranjo-Escobar J, López D, Bedoya-Joaqui V, Nieto-Aristizábal I, Castro AM, Díaz-Ordoñez L, Navarro EP, Barrera MC, Echeverri A, Cañas CA, Tobón GJ. Expression of BAFF, APRIL, and cognate receptor genes in lupus nephritis and potential use as urinary biomarkers. J Transl Autoimmun 2020;3:100027. [PMID: 32743512 DOI: 10.1016/j.jtauto.2019.100027] [Reference Citation Analysis]
53 Kamhieh-milz J, Ghosoun N, Sterzer V, Salama A. Effect of glucocorticoid treatment on BAFF and APRIL expression in patients with immune thrombocytopenia (ITP). Clinical Immunology 2018;188:74-80. [DOI: 10.1016/j.clim.2017.12.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
54 Duan L, Chen L, Zhong S, Wang Y, Huang Y, He Y, Chen J, Shi G. Treatment of Bullous Systemic Lupus Erythematosus. J Immunol Res 2015;2015:167064. [PMID: 26090480 DOI: 10.1155/2015/167064] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
55 Luo S, Ding S, Liao J, Zhang P, Liu Y, Zhao M, Lu Q. Excessive miR-152-3p Results in Increased BAFF Expression in SLE B-Cells by Inhibiting the KLF5 Expression. Front Immunol 2019;10:1127. [PMID: 31178864 DOI: 10.3389/fimmu.2019.01127] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
56 Abe T, AlSarhan M, Benakanakere MR, Maekawa T, Kinane DF, Cancro MP, Korostoff JM, Hajishengallis G. The B Cell-Stimulatory Cytokines BLyS and APRIL Are Elevated in Human Periodontitis and Are Required for B Cell-Dependent Bone Loss in Experimental Murine Periodontitis. J Immunol 2015;195:1427-35. [PMID: 26150532 DOI: 10.4049/jimmunol.1500496] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
57 Hajishengallis G, Chavakis T, Lambris JD. Current understanding of periodontal disease pathogenesis and targets for host-modulation therapy. Periodontol 2000 2020;84:14-34. [PMID: 32844416 DOI: 10.1111/prd.12331] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 24.0] [Reference Citation Analysis]
58 Vincent FB, Kandane-Rathnayake R, Koelmeyer R, Harris J, Hoi AY, Mackay F, Morand EF. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus. Lupus Sci Med 2020;7:e000375. [PMID: 32546562 DOI: 10.1136/lupus-2019-000375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
59 Yoshitomi H. Regulation of Immune Responses and Chronic Inflammation by Fibroblast-Like Synoviocytes. Front Immunol 2019;10:1395. [PMID: 31275325 DOI: 10.3389/fimmu.2019.01395] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 21.0] [Reference Citation Analysis]
60 Hébert V, Maho-Vaillant M, Golinski ML, Petit M, Riou G, Boyer O, Musette P, Calbo S, Joly P. Modifications of the BAFF/BAFF-Receptor Axis in Patients With Pemphigus Treated With Rituximab Versus Standard Corticosteroid Regimen. Front Immunol 2021;12:666022. [PMID: 34054835 DOI: 10.3389/fimmu.2021.666022] [Reference Citation Analysis]
61 Morand EF, Isenberg DA, Wallace DJ, Kao AH, Vazquez-Mateo C, Chang P, Pudota K, Aranow C, Merrill JT. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford) 2020;59:2930-8. [PMID: 32107560 DOI: 10.1093/rheumatology/keaa029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
62 Friebus-kardash J, Branco L, Ribi C, Chizzolini C, Huynh-do U, Dubler D, Roux-lombard P, Dolff S, Kribben A, Eisenberger U, Trendelenburg M. Immune complexes containing serum B-cell activating factor and immunoglobulin G correlate with disease activity in systemic lupus erythematosus. Nephrology Dialysis Transplantation 2018;33:54-64. [DOI: 10.1093/ndt/gfx220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
63 Georg I, Díaz-Barreiro A, Morell M, Pey AL, Alarcón-Riquelme ME. BANK1 interacts with TRAF6 and MyD88 in innate immune signaling in B cells. Cell Mol Immunol 2020;17:954-65. [PMID: 31243359 DOI: 10.1038/s41423-019-0254-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
64 Lee C, Park JW, Suh JH, Moon KC. High expression of APRIL correlates with poor prognosis in clear cell renal cell carcinoma. Pathol Res Pract 2015;211:824-8. [PMID: 26296917 DOI: 10.1016/j.prp.2015.07.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
65 Vincent FB, Kandane-Rathnayake R, Hoi AY, Slavin L, Godsell JD, Kitching AR, Harris J, Nelson CL, Jenkins AJ, Chrysostomou A, Hibbs ML, Kerr PG, Rischmueller M, Mackay F, Morand EF. Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus. Lupus 2018;27:2029-40. [PMID: 30301439 DOI: 10.1177/0961203318804885] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
66 Parodis I, Zickert A, Sundelin B, Axelsson M, Gerhardsson J, Svenungsson E, Malmström V, Gunnarsson I. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci Med 2015;2:e000061. [PMID: 25632350 DOI: 10.1136/lupus-2014-000061] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
67 Chimote AA, Hajdu P, Kottyan LC, Harley JB, Yun Y, Conforti L. Nanovesicle-targeted Kv1.3 knockdown in memory T cells suppresses CD40L expression and memory phenotype. J Autoimmun 2016;69:86-93. [PMID: 26994905 DOI: 10.1016/j.jaut.2016.03.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
68 Frieri M, Heuser W, Bliss J. Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis. J Pharmacol Pharmacother 2015;6:71-6. [PMID: 25969652 DOI: 10.4103/0976-500X.155482] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
69 Lin X, Lu L. B Cell-Mediated Autoimmune Diseases. Adv Exp Med Biol 2020;1254:145-60. [PMID: 32323275 DOI: 10.1007/978-981-15-3532-1_11] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Bassi N, Luisetto R, Ghirardello A, Gatto M, Valente M, Della Barbera M, Nalotto L, Punzi L, Doria A. 17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice. Lupus 2015;24:382-91. [PMID: 25801881 DOI: 10.1177/0961203314559636] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
71 Wekerle H. B cells in multiple sclerosis. Autoimmunity 2017;50:57-60. [PMID: 28166681 DOI: 10.1080/08916934.2017.1281914] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 12.5] [Reference Citation Analysis]
72 Parackova Z, Klocperk A, Rataj M, Kayserova J, Zentsova I, Sumnik Z, Kolouskova S, Sklenarova J, Pruhova S, Obermannova B, Petruzelkova L, Lebl J, Kalina T, Sediva A. Alteration of B cell subsets and the receptor for B cell activating factor (BAFF) in paediatric patients with type 1 diabetes. Immunol Lett 2017;189:94-100. [PMID: 28414179 DOI: 10.1016/j.imlet.2017.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
73 Wilhelmson AS, Lantero Rodriguez M, Stubelius A, Fogelstrand P, Johansson I, Buechler MB, Lianoglou S, Kapoor VN, Johansson ME, Fagman JB, Duhlin A, Tripathi P, Camponeschi A, Porse BT, Rolink AG, Nissbrandt H, Turley SJ, Carlsten H, Mårtensson IL, Karlsson MCI, Tivesten Å. Testosterone is an endogenous regulator of BAFF and splenic B cell number. Nat Commun 2018;9:2067. [PMID: 29802242 DOI: 10.1038/s41467-018-04408-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
74 Croft M, Siegel RM. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat Rev Rheumatol 2017;13:217-33. [PMID: 28275260 DOI: 10.1038/nrrheum.2017.22] [Cited by in Crossref: 120] [Cited by in F6Publishing: 114] [Article Influence: 30.0] [Reference Citation Analysis]
75 Uzzan M, Colombel JF, Cerutti A, Treton X, Mehandru S. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Dig Dis Sci 2016;61:3407-24. [PMID: 27655102 DOI: 10.1007/s10620-016-4317-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
76 Morais SA, Vilas-Boas A, Isenberg DA. B-cell survival factors in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 2015;7:122-51. [PMID: 26288664 DOI: 10.1177/1759720X15586782] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
77 Huang Z, Chen B, Liu X, Li H, Xie L, Gao Y, Duan R, Li Z, Zhang J, Zheng Y, Su W. Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis. Proc Natl Acad Sci U S A 2021;118:e2023216118. [PMID: 34385315 DOI: 10.1073/pnas.2023216118] [Reference Citation Analysis]
78 Liu J, Huang X, Hao S, Wang Y, Liu M, Xu J, Zhang X, Yu T, Gan S, Dai D, Luo X, Lu Q, Mao C, Zhang Y, Shen N, Li B, Huang M, Zhu X, Jin J, Cheng X, Sun SC, Xiao Y. Peli1 negatively regulates noncanonical NF-κB signaling to restrain systemic lupus erythematosus. Nat Commun 2018;9:1136. [PMID: 29555915 DOI: 10.1038/s41467-018-03530-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
79 Zeng Q, Zhou Z, Qin S, Yao Y, Qin J, Zhang H, Zhang R, Xu C, Zhang S, Huang S, Chen L. Rapamycin inhibits B-cell activating factor (BAFF)-stimulated cell proliferation and survival by suppressing Ca2+-CaMKII-dependent PTEN/Akt-Erk1/2 signaling pathway in normal and neoplastic B-lymphoid cells. Cell Calcium 2020;87:102171. [PMID: 32062191 DOI: 10.1016/j.ceca.2020.102171] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
80 Ge F, Wang F, Yan X, Li Z, Wang X. Association of BAFF with PI3K/Akt/mTOR signaling in lupus nephritis. Mol Med Rep 2017;16:5793-8. [PMID: 28849060 DOI: 10.3892/mmr.2017.7367] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
81 Dong G, Yang Y, Li X, Yao X, Zhu Y, Zhang H, Wang H, Ma Q, Zhang J, Shi H, Ning Z, Yan F, Zhai W, Dai J, Li Z, Li C, Ming J, Xue Q, Meng X, Si C, Xiong H. Granulocytic myeloid-derived suppressor cells contribute to IFN-I signaling activation of B cells and disease progression through the lncRNA NEAT1-BAFF axis in systemic lupus erythematosus. Biochim Biophys Acta Mol Basis Dis 2020;1866:165554. [PMID: 31513833 DOI: 10.1016/j.bbadis.2019.165554] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
82 Shurin MR, Ma Y, Keskinov AA, Zhao R, Lokshin A, Agassandian M, Shurin GV. BAFF and APRIL from Activin A-Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells In Vivo. Cancer Res 2016;76:4959-69. [PMID: 27364554 DOI: 10.1158/0008-5472.CAN-15-2668] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
83 Guzman M, Hui-Yuen JS. Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab. Drug Des Devel Ther 2020;14:2503-13. [PMID: 32612353 DOI: 10.2147/DDDT.S216193] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
84 Tang F, Chen X, Mao Y, Wan S, Ai S, Yang H, Liu G, Zou Y, Lin M, Dan L. Orbital fibroblasts of Graves' orbitopathy stimulated with proinflammatory cytokines promote B cell survival by secreting BAFF. Mol Cell Endocrinol 2017;446:1-11. [PMID: 28087387 DOI: 10.1016/j.mce.2017.01.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
85 Bag-Ozbek A, Hui-Yuen JS. Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag 2021;17:39-54. [PMID: 33488082 DOI: 10.2147/TCRM.S252592] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
86 Giltiay NV, Shu GL, Shock A, Clark EA. Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling. Arthritis Res Ther 2017;19:91. [PMID: 28506291 DOI: 10.1186/s13075-017-1284-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
87 Li X, Ding Y, Zi M, Sun L, Zhang W, Chen S, Xu Y. CD19, from bench to bedside. Immunology Letters 2017;183:86-95. [DOI: 10.1016/j.imlet.2017.01.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
88 Khodadadi L, Cheng Q, Alexander T, Sercan-Alp Ö, Klotsche J, Radbruch A, Hiepe F, Hoyer BF, Taddeo A. Bortezomib Plus Continuous B Cell Depletion Results in Sustained Plasma Cell Depletion and Amelioration of Lupus Nephritis in NZB/W F1 Mice. PLoS One 2015;10:e0135081. [PMID: 26252021 DOI: 10.1371/journal.pone.0135081] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
89 Amaya-Uribe L, Rojas M, Azizi G, Anaya JM, Gershwin ME. Primary immunodeficiency and autoimmunity: A comprehensive review. J Autoimmun 2019;99:52-72. [PMID: 30795880 DOI: 10.1016/j.jaut.2019.01.011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 16.0] [Reference Citation Analysis]
90 Rubin SJS, Bloom MS, Robinson WH. B cell checkpoints in autoimmune rheumatic diseases. Nat Rev Rheumatol 2019;15:303-15. [PMID: 30967621 DOI: 10.1038/s41584-019-0211-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 17.0] [Reference Citation Analysis]
91 Alvarez-Rodriguez L, Riancho-Zarrabeitia L, Calvo-Alén J, López-Hoyos M, Martínez-Taboada V. Peripheral B-Cell Subset Distribution in Primary Antiphospholipid Syndrome. Int J Mol Sci 2018;19:E589. [PMID: 29462939 DOI: 10.3390/ijms19020589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
92 Traub J, Häusser-Kinzel S, Weber MS. Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients. Int J Mol Sci 2020;21:E5021. [PMID: 32708663 DOI: 10.3390/ijms21145021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
93 Akita K, Yasaka K, Shirai T, Ishii T, Harigae H, Fujii H. Interferon α Enhances B Cell Activation Associated With FOXM1 Induction: Potential Novel Therapeutic Strategy for Targeting the Plasmablasts of Systemic Lupus Erythematosus. Front Immunol 2020;11:498703. [PMID: 33633721 DOI: 10.3389/fimmu.2020.498703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
94 González LA, Ugarte-Gil MF, Alarcón GS. Systemic lupus erythematosus: The search for the ideal biomarker. Lupus 2021;30:181-203. [PMID: 33307987 DOI: 10.1177/0961203320979051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Masoumi M, Bashiri H, Khorramdelazad H, Barzaman K, Hashemi N, Sereshki HA, Sahebkar A, Karami J. Destructive Roles of Fibroblast-like Synoviocytes in Chronic Inflammation and Joint Damage in Rheumatoid Arthritis. Inflammation 2021;44:466-79. [PMID: 33113036 DOI: 10.1007/s10753-020-01371-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
96 Sun B, Xia Z, Cai F, Wang P, Xu M, Wu Y. APRIL is Involved in the Proliferation and Metastasis of Acute Lymphoblastic Leukemia Cells. J Pediatr Hematol Oncol 2018;40:588-93. [PMID: 29697578 DOI: 10.1097/MPH.0000000000001198] [Reference Citation Analysis]
97 Vilas-Boas A, Morais SA, Isenberg DA. Belimumab in systemic lupus erythematosus. RMD Open 2015;1:e000011. [PMID: 26509047 DOI: 10.1136/rmdopen-2014-000011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
98 Seys LJ, Verhamme FM, Schinwald A, Hammad H, Cunoosamy DM, Bantsimba-Malanda C, Sabirsh A, McCall E, Flavell L, Herbst R, Provoost S, Lambrecht BN, Joos GF, Brusselle GG, Bracke KR. Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2015;192:706-18. [PMID: 26266827 DOI: 10.1164/rccm.201501-0103OC] [Cited by in Crossref: 65] [Cited by in F6Publishing: 37] [Article Influence: 10.8] [Reference Citation Analysis]
99 Klein A, Polliack A, Gafter-Gvili A. Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology. Leuk Res 2018;75:45-9. [PMID: 30458319 DOI: 10.1016/j.leukres.2018.11.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
100 Hui-Yuen JS, Li XQ, Askanase AD. Belimumab in systemic lupus erythematosus: a perspective review. Ther Adv Musculoskelet Dis 2015;7:115-21. [PMID: 26288663 DOI: 10.1177/1759720X15588514] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
101 Robert M, Miossec P. Interleukin-17 and lupus: enough to be a target? For which patients? Lupus 2020;29:6-14. [PMID: 31791181 DOI: 10.1177/0961203319891243] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
102 Friebus-Kardash J, Trendelenburg M, Eisenberger U, Ribi C, Chizzolini C, Huynh-Do U, Lang KS, Wilde B, Kribben A, Witzke O, Dolff S, Hardt C. Susceptibility of BAFF-var allele carriers to severe SLE with occurrence of lupus nephritis. BMC Nephrol 2019;20:430. [PMID: 31752784 DOI: 10.1186/s12882-019-1623-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
103 Song S. Alpha-1 Antitrypsin Therapy for Autoimmune Disorders. Chronic Obstr Pulm Dis 2018;5:289-301. [PMID: 30723786 DOI: 10.15326/jcopdf.5.4.2018.0131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
104 Muema DM, Macharia GN, Hassan AS, Mwaringa SM, Fegan GW, Berkley JA, Nduati EW, Urban BC. Control of Viremia Enables Acquisition of Resting Memory B Cells with Age and Normalization of Activated B Cell Phenotypes in HIV-Infected Children. J Immunol 2015;195:1082-91. [PMID: 26116511 DOI: 10.4049/jimmunol.1500491] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
105 Wang X, Wei Y, Xiao H, Liu X, Zhang Y, Han G, Chen G, Hou C, Ma N, Shen B, Li Y, Egwuagu CE, Wang R. A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice: Molecular immunology. Eur J Immunol 2016;46:1343-50. [DOI: 10.1002/eji.201546095] [Cited by in Crossref: 81] [Cited by in F6Publishing: 83] [Article Influence: 16.2] [Reference Citation Analysis]
106 James JA, Guthridge JM, Chen H, Lu R, Bourn RL, Bean K, Munroe ME, Smith M, Chakravarty E, Baer AN, Noaiseh G, Parke A, Boyle K, Keyes-Elstein L, Coca A, Utset T, Genovese MC, Pascual V, Utz PJ, Holers VM, Deane KD, Sivils KL, Aberle T, Wallace DJ, McNamara J, Franchimont N, St Clair EW. Unique Sjögren's syndrome patient subsets defined by molecular features. Rheumatology (Oxford) 2020;59:860-8. [PMID: 31497844 DOI: 10.1093/rheumatology/kez335] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
107 Dieudonné Y, Guffroy A, Poindron V, Sprauel PS, Martin T, Korganow AS, Gies V. B cells in primary antiphospholipid syndrome: Review and remaining challenges. Autoimmun Rev 2021;20:102798. [PMID: 33722752 DOI: 10.1016/j.autrev.2021.102798] [Reference Citation Analysis]
108 Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv 2019;3:3248-60. [PMID: 31698455 DOI: 10.1182/bloodadvances.2019000703] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 30.0] [Reference Citation Analysis]
109 Lee C, Wang C, Chen M, Chuang K, Cheng T, Jian T, Wang Y, Huang T, Liao K, Tzou S. Development of an inflammatory tissue-selective chimeric TNF receptor. Cytokine 2019;113:340-6. [DOI: 10.1016/j.cyto.2018.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
110 Xu Z, Zhao B, Xiong H, Wei B, Wang Y. Serum BAFF and APRIL levels in patients with autoimmune hemolytic anemia and their clinical significance. Int J Hematol 2015;102:394-400. [DOI: 10.1007/s12185-015-1851-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
111 Yamaguchi H, Goto S, Takahashi N, Tsuchida M, Watanabe H, Yamamoto S, Kaneko Y, Higashi K, Mori H, Nakamura Y, Horii A, Kurokawa K, Narita I. Aberrant mucosal immunoreaction to tonsillar microbiota in immunoglobulin A nephropathy. Nephrol Dial Transplant. 2021;36:75-86. [PMID: 33099625 DOI: 10.1093/ndt/gfaa223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
112 Schuh E, Musumeci A, Thaler FS, Laurent S, Ellwart JW, Hohlfeld R, Krug A, Meinl E. Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement. J I 2017;198:3081-8. [DOI: 10.4049/jimmunol.1601746] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
113 Xiao X, Lian M, Zhang W, Eric Gershwin M, Ma X. The Immunologic Paradoxes of IgG4-Related Disease. Clin Rev Allergy Immunol. 2018;54:344-351. [PMID: 29460058 DOI: 10.1007/s12016-018-8679-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
114 Ghirardello A, Gizzo S, Noventa M, Quaranta M, Vitagliano A, Gallo N, Pantano G, Beggio M, Cosma C, Gangemi M, Plebani M, Doria A. Acute immunomodulatory changes during controlled ovarian stimulation: evidence from the first trial investigating the short-term effects of estradiol on biomarkers and B cells involved in autoimmunity. J Assist Reprod Genet 2015;32:1765-72. [PMID: 26466939 DOI: 10.1007/s10815-015-0588-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
115 Liang Y, Kahlenberg JM, Gudjonsson JE. A vestigial pathway for sex differences in immune regulation. Cell Mol Immunol 2017;14:578-80. [PMID: 28529333 DOI: 10.1038/cmi.2017.28] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Choi SC, Morel L. B cell contribution of the CD4+ T cell inflammatory phenotypes in systemic lupus erythematosus. Autoimmunity 2017;50:37-41. [PMID: 28166683 DOI: 10.1080/08916934.2017.1280028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
117 Pongpirul W, Chancharoenthana W, Pongpirul K, Leelahavanichkul A, Kittikowit W, Jutivorakool K, Nonthasoot B, Avihingsanon Y, Eiam-Ong S, Praditpornsilpa K, Townamchai N. B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients. Nephrology (Carlton) 2018;23:169-74. [PMID: 27888573 DOI: 10.1111/nep.12972] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
118 Sonar S, Lal G. Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity. Front Immunol 2015;6:364. [PMID: 26257732 DOI: 10.3389/fimmu.2015.00364] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
119 Binda V, Trezzi B, Del Papa N, Beretta L, Frontini G, Porata G, Fabbrini P, Pozzi MR, Messa P, Sinico RA, Moroni G. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient). J Nephrol 2020;33:1019-25. [DOI: 10.1007/s40620-020-00706-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
120 De Silva NS, Silva K, Anderson MM, Bhagat G, Klein U. Impairment of Mature B Cell Maintenance upon Combined Deletion of the Alternative NF-κB Transcription Factors RELB and NF-κB2 in B Cells. J Immunol 2016;196:2591-601. [PMID: 26851215 DOI: 10.4049/jimmunol.1501120] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
121 Maria NI, Vogelsang P, Versnel MA. The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to man. Arthritis Res Ther 2015;17:172. [PMID: 26137972 DOI: 10.1186/s13075-015-0678-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
122 González-Serna D, Ortiz-Fernández L, Vargas S, García A, Raya E, Fernández-Gutierrez B, López-Longo FJ, Balsa A, González-Álvaro I, Narvaez J, Gómez-Vaquero C, Sabio JM, García-Portales R, González-Escribano MF, Tolosa C, Carreira P, Kiemeney L, Coenen MJH, Witte T, Schneider M, González-Gay MÁ, Martín J. Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus. Sci Rep 2018;8:8195. [PMID: 29844438 DOI: 10.1038/s41598-018-26573-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
123 Godahewa G, Perera N, Umasuthan N, Wan Q, Whang I, Lee J. Molecular characterization and expression analysis of B cell activating factor from rock bream (Oplegnathus fasciatus). Developmental & Comparative Immunology 2016;55:1-11. [DOI: 10.1016/j.dci.2015.10.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
124 Linher-Melville K, Shah A, Singh G. Sex differences in neuro(auto)immunity and chronic sciatic nerve pain. Biol Sex Differ 2020;11:62. [PMID: 33183347 DOI: 10.1186/s13293-020-00339-y] [Reference Citation Analysis]
125 Mourik BC, Lubberts E, de Steenwinkel JEM, Ottenhoff THM, Leenen PJM. Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases. Front Immunol 2017;8:294. [PMID: 28424682 DOI: 10.3389/fimmu.2017.00294] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
126 Bertsias G, Fanouriakis A, Boumpas DT. Treatment of Systemic Lupus Erythematosus. Kelley and Firestein's Textbook of Rheumatology. Elsevier; 2017. pp. 1368-1388.e5. [DOI: 10.1016/b978-0-323-31696-5.00081-4] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
127 Müller-Winkler J, Mitter R, Rappe JCF, Vanes L, Schweighoffer E, Mohammadi H, Wack A, Tybulewicz VLJ. Critical requirement for BCR, BAFF, and BAFFR in memory B cell survival. J Exp Med 2021;218:e20191393. [PMID: 33119032 DOI: 10.1084/jem.20191393] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
128 Yeo SC, Liew A, Barratt J. Emerging therapies in immunoglobulin A nephropathy. Nephrology (Carlton) 2015;20:788-800. [PMID: 26032537 DOI: 10.1111/nep.12527] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
129 Dostert C, Grusdat M, Letellier E, Brenner D. The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond. Physiological Reviews 2019;99:115-60. [DOI: 10.1152/physrev.00045.2017] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 38.0] [Reference Citation Analysis]
130 van den Hoogen LL, Palla G, Bekker CPJ, Fritsch-Stork RDE, Radstake TRDJ, van Roon JAG. Increased B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores. RMD Open 2018;4:e000693. [PMID: 30018806 DOI: 10.1136/rmdopen-2018-000693] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
131 Hirose M, Arai T, Sugimoto C, Takimoto T, Sugawara R, Minomo S, Shintani S, Takeuchi N, Katayama K, Inoue Y, Kagawa T, Kasai T, Akira M, Inoue Y. B cell-activating factors in autoimmune pulmonary alveolar proteinosis. Orphanet J Rare Dis 2021;16:115. [PMID: 33653382 DOI: 10.1186/s13023-021-01755-y] [Reference Citation Analysis]
132 Lee DSW, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 2021;20:179-99. [PMID: 33324003 DOI: 10.1038/s41573-020-00092-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 19.0] [Reference Citation Analysis]
133 Ehrenstein MR, Wing C. The BAFFling effects of rituximab in lupus: danger ahead? Nat Rev Rheumatol. 2016;12:367-372. [PMID: 26888554 DOI: 10.1038/nrrheum.2016.18] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 11.4] [Reference Citation Analysis]
134 Yeo SC, Liew A. Biologic agents in the treatment of glomerulonephritides. Nephrology (Carlton) 2015;20:767-87. [PMID: 26040770 DOI: 10.1111/nep.12530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
135 Akizuki S, Ishigaki K, Kochi Y, Law S, Matsuo K, Ohmura K, Suzuki A, Nakayama M, Iizuka Y, Koseki H, Ohara O, Hirata J, Kamatani Y, Matsuda F, Sumida T, Yamamoto K, Okada Y, Mimori T, Terao C. PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes. Ann Rheum Dis 2019;78:509-18. [DOI: 10.1136/annrheumdis-2018-214116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
136 Zhan Y, Carrington EM, Ko H, Vikstrom IB, Oon S, Zhang J, Vremec D, Brady JL, Bouillet P, Wu L, Huang DCS, Wicks IP, Morand EF, Strasser A, Lew AM. Bcl-2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupus-Prone Mice and Dampen Interferon-α Production: Bcl-2 Antagonists Kill Lupus PDCs. Arthritis & Rheumatology 2015;67:797-808. [DOI: 10.1002/art.38966] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
137 Wang X, Zhang Y, Wang Z, Liu X, Zhu G, Han G, Chen G, Hou C, Wang T, Shen B, Li Y, Xiao H, Ma N, Wang R. Anti‑IL‑39 (IL‑23p19/Ebi3) polyclonal antibodies ameliorate autoimmune symptoms in lupus‑like mice. Mol Med Rep 2018;17:1660-6. [PMID: 29138852 DOI: 10.3892/mmr.2017.8048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
138 Gatto M, Saccon F, Zen M, Bettio S, Iaccarino L, Punzi L, Doria A. Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. J Autoimmun 2016;74:94-105. [PMID: 27373904 DOI: 10.1016/j.jaut.2016.06.014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
139 Matusik PS, Matusik PT, Stein PK. Heart rate variability in patients with systemic lupus erythematosus: a systematic review and methodological considerations. Lupus 2018;27:1225-39. [PMID: 29697012 DOI: 10.1177/0961203318771502] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
140 Mortazavi SE, Lugaajju A, Kaddumukasa M, Tijani MK, Kironde F, Persson KEM. Osteopontin and malaria: no direct effect on parasite growth, but correlation with P. falciparum-specific B cells and BAFF in a malaria endemic area. BMC Microbiol 2021;21:307. [PMID: 34742229 DOI: 10.1186/s12866-021-02368-y] [Reference Citation Analysis]
141 Kim CW, Oh JE, Lee HK. Single Cell Transcriptomic Re-analysis of Immune Cells in Bronchoalveolar Lavage Fluids Reveals the Correlation of B Cell Characteristics and Disease Severity of Patients with SARS-CoV-2 Infection. Immune Netw 2021;21:e10. [PMID: 33728103 DOI: 10.4110/in.2021.21.e10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
142 Figgett WA, Deliyanti D, Fairfax KA, Quah PS, Wilkinson-berka JL, Mackay F. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers. Journal of Autoimmunity 2015;61:9-16. [DOI: 10.1016/j.jaut.2015.04.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
143 Traub J, Husseini L, Weber MS. B Cells and Antibodies as Targets of Therapeutic Intervention in Neuromyelitis Optica Spectrum Disorders. Pharmaceuticals (Basel) 2021;14:37. [PMID: 33419217 DOI: 10.3390/ph14010037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
144 Wei Y, Lao XM, Xiao X, Wang XY, Wu ZJ, Zeng QH, Wu CY, Wu RQ, Chen ZX, Zheng L, Li B, Kuang DM. Plasma Cell Polarization to the Immunoglobulin G Phenotype in Hepatocellular Carcinomas Involves Epigenetic Alterations and Promotes Hepatoma Progression in Mice. Gastroenterology 2019;156:1890-1904.e16. [PMID: 30711627 DOI: 10.1053/j.gastro.2019.01.250] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
145 Saidoune F, Even G, Lamri Y, Chezel J, Gaston AT, Escoubet B, Papo T, Charles N, Nicoletti A, Sacre K. Effects of BAFF Neutralization on Atherosclerosis Associated With Systemic Lupus Erythematosus. Arthritis Rheumatol 2021;73:255-64. [PMID: 32783382 DOI: 10.1002/art.41485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
146 Wu DH, Xu L, Wen CP, Xie GQ, Ji JJ, Pan JL, Jiao YF, Fan YS. The effects of Jieduquyuzishen prescription-treated rat serum on the BAFF/BAFF-R signal pathway. PLoS One 2015;10:e0118462. [PMID: 25689512 DOI: 10.1371/journal.pone.0118462] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
147 Figgett WA, Monaghan K, Ng M, Alhamdoosh M, Maraskovsky E, Wilson NJ, Hoi AY, Morand EF, Mackay F. Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus. Clin Transl Immunology 2019;8:e01093. [PMID: 31921420 DOI: 10.1002/cti2.1093] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
148 Zhang T, De Carolis C, Man GCW, Wang CC. The link between immunity, autoimmunity and endometriosis: a literature update. Autoimmun Rev 2018;17:945-55. [PMID: 30107265 DOI: 10.1016/j.autrev.2018.03.017] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
149 Vilas-boas A, Bakshi J, Isenberg DA. What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy? Expert Review of Clinical Immunology 2015;11:1093-107. [DOI: 10.1586/1744666x.2015.1078237] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
150 Lunde S, Kristoffersen EK, Sapkota D, Risa K, Dahl O, Bruland O, Mella O, Fluge Ø. Serum BAFF and APRIL Levels, T-Lymphocyte Subsets, and Immunoglobulins after B-Cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Myalgic Encephalopathy/Chronic Fatigue Syndrome. PLoS One 2016;11:e0161226. [PMID: 27536947 DOI: 10.1371/journal.pone.0161226] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
151 Ward-Kavanagh LK, Lin WW, Šedý JR, Ware CF. The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity 2016;44:1005-19. [PMID: 27192566 DOI: 10.1016/j.immuni.2016.04.019] [Cited by in Crossref: 169] [Cited by in F6Publishing: 156] [Article Influence: 42.3] [Reference Citation Analysis]
152 Phatak S, Chaurasia S, Mishra SK, Gupta R, Agrawal V, Aggarwal A, Misra R. Urinary B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL): potential biomarkers of active lupus nephritis. Clin Exp Immunol 2017;187:376-82. [PMID: 27804111 DOI: 10.1111/cei.12894] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
153 Ettinger R, Karnell JL, Henault J, Panda SK, Riggs JM, Kolbeck R, Sanjuan MA. Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses. Autoimmunity 2017;50:25-36. [PMID: 28166684 DOI: 10.1080/08916934.2017.1280670] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
154 Kallenberg CG, Hauser T. B-cell therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 2015;30 Suppl 1:i119-22. [PMID: 25753806 DOI: 10.1093/ndt/gfv056] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
155 Vincent FB, Slavin L, Hoi AY, Kitching AR, Mackay F, Harris J, Kandane-Rathnayake R, Morand EF. Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosus. Lupus Sci Med 2018;5:e000277. [PMID: 30397495 DOI: 10.1136/lupus-2018-000277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
156 Li XY, Duan HJ, Liu XY, Deng XL. Change of serum B-cell activating factor level in patients with positive antiphospholipid antibodies and previous adverse pregnancy outcomes and its significance. Chin Med J (Engl) 2020;133:2287-94. [PMID: 32842014 DOI: 10.1097/CM9.0000000000000948] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Wang H, Wang J, Xia Y. Defective Suppressor of Cytokine Signaling 1 Signaling Contributes to the Pathogenesis of Systemic Lupus Erythematosus. Front Immunol 2017;8:1292. [PMID: 29085365 DOI: 10.3389/fimmu.2017.01292] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
158 Carrillo-Ballesteros FJ, Palafox-Sánchez CA, Franco-Topete RA, Muñoz-Valle JF, Orozco-Barocio G, Martínez-Bonilla GE, Gómez-López CE, Marín-Rosales M, López-Villalobos EF, Luquin S, Castañeda-Chávez A, Oregon-Romero E. Expression of BAFF and BAFF receptors in primary Sjögren's syndrome patients with ectopic germinal center-like structures. Clin Exp Med 2020;20:615-26. [PMID: 32506205 DOI: 10.1007/s10238-020-00637-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
159 Guiteras J, Ripoll É, Bolaños N, De Ramon L, Fontova P, Lloberas N, Cruzado JM, Aràn JM, Aviñó A, Eritja R, Gomà M, Taco R, Grinyó JM, Torras J. The gene silencing of IRF5 and BLYSS effectively modulates the outcome of experimental lupus nephritis. Mol Ther Nucleic Acids 2021;24:807-21. [PMID: 33996261 DOI: 10.1016/j.omtn.2021.03.019] [Reference Citation Analysis]
160 Mulazzani M, Huber M, Borchard S, Langer S, Angele B, Schuh E, Meinl E, Dreyling M, Birnbaum T, Straube A, Koedel U, von Baumgarten L. APRIL and BAFF: novel biomarkers for central nervous system lymphoma. J Hematol Oncol 2019;12:102. [PMID: 31615554 DOI: 10.1186/s13045-019-0796-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
161 Liu C, Tsai C, Chiang S, Tang S, Chen N, Mak TW, Sun G, Sun K. Triggering receptor expressed on myeloid cells-1 (TREM-1) deficiency augments BAFF production to promote lupus progression. Journal of Autoimmunity 2017;78:92-100. [DOI: 10.1016/j.jaut.2016.12.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
162 Celhar T, Fairhurst AM. Modelling clinical systemic lupus erythematosus: similarities, differences and success stories. Rheumatology (Oxford) 2017;56:i88-99. [PMID: 28013204 DOI: 10.1093/rheumatology/kew400] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
163 Blanco P, Ueno H, Schmitt N. T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis: HIGHLIGHTS. Eur J Immunol 2016;46:281-90. [DOI: 10.1002/eji.201545760] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 14.6] [Reference Citation Analysis]
164 Dema B, Charles N. Autoantibodies in SLE: Specificities, Isotypes and Receptors. Antibodies (Basel) 2016;5:E2. [PMID: 31557984 DOI: 10.3390/antib5010002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
165 García-Guerrero E, Sierro-Martínez B, Pérez-Simón JA. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma. Front Immunol 2020;11:1128. [PMID: 32582204 DOI: 10.3389/fimmu.2020.01128] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
166 Sjöstrand M, Johansson A, Aqrawi L, Olsson T, Wahren-Herlenius M, Espinosa A. The Expression of BAFF Is Controlled by IRF Transcription Factors. J Immunol 2016;196:91-6. [PMID: 26590315 DOI: 10.4049/jimmunol.1501061] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
167 Martín-Penagos L, Fernández-Fresnedo G, Benito-Hernández A, Mazón J, de Cos M, Oviedo MV, San Segundo D, López-Hoyos M, Gómez-Román J, Ruiz JC, Rodrigo E. [Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression]. Nefrologia (Engl Ed) 2021;41:311-20. [PMID: 33741175 DOI: 10.1016/j.nefro.2020.12.011] [Reference Citation Analysis]
168 Ding Y, Liao W, He XJ, Xiang W. Effects of 1,25(OH)2 D3 and vitamin D receptor on peripheral CD4+ /CD8+ double-positive T lymphocytes in a mouse model of systemic lupus erythematosus. J Cell Mol Med 2017;21:975-85. [PMID: 28063200 DOI: 10.1111/jcmm.13037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
169 Liu CJ, Tang SJ, Chou CC, Sun GH, Sun KH. In Vivo Suppression of Autophagy via Lentiviral shRNA Targeting Atg5 Improves Lupus-Like Syndrome. Biomed Res Int 2020;2020:8959726. [PMID: 32462028 DOI: 10.1155/2020/8959726] [Reference Citation Analysis]
170 Xie C, Quan R, Wang L, Chen C, Yan W, Fu Y. Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort. Clin Exp Immunol 2019;198:131-40. [PMID: 31314927 DOI: 10.1111/cei.13350] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
171 Martín-Penagos L, Fernández-Fresnedo G, Benito-Hernández A, Mazón J, de Cos M, Oviedo MV, San Segundo D, López-Hoyos M, Gómez-Román J, Ruiz JC, Rodrigo E. Measurement of galactosyl-deficient IgA1 by the monoclonal antibody KM55 contributes to predicting patients with IgA nephropathy with high risk of long-term progression. Nefrologia 2021:S2013-2514(21)00058-4. [PMID: 34330689 DOI: 10.1016/j.nefroe.2021.06.004] [Reference Citation Analysis]
172 Jonsson S, Sveinbjornsson G, de Lapuente Portilla AL, Swaminathan B, Plomp R, Dekkers G, Ajore R, Ali M, Bentlage AEH, Elmér E, Eyjolfsson GI, Gudjonsson SA, Gullberg U, Gylfason A, Halldorsson BV, Hansson M, Holm H, Johansson Å, Johnsson E, Jonasdottir A, Ludviksson BR, Oddsson A, Olafsson I, Olafsson S, Sigurdardottir O, Sigurdsson A, Stefansdottir L, Masson G, Sulem P, Wuhrer M, Wihlborg A, Thorleifsson G, Gudbjartsson DF, Thorsteinsdottir U, Vidarsson G, Jonsdottir I, Nilsson B, Stefansson K. Identification of sequence variants influencing immunoglobulin levels. Nat Genet 2017;49:1182-91. [DOI: 10.1038/ng.3897] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 11.8] [Reference Citation Analysis]
173 Henrickson SE, Ruffner MA, Kwan M. Unintended Immunological Consequences of Biologic Therapy. Curr Allergy Asthma Rep 2016;16:46. [PMID: 27324478 DOI: 10.1007/s11882-016-0624-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
174 Madhuranga W, Tharuka MN, Yang H, Lim C, Wan Q, Bathige S, Lee J. Molecular expression analysis and characterization of rockfish (Sebastes schlegelii) B cell activating factor. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology 2020;250:110480. [DOI: 10.1016/j.cbpb.2020.110480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
175 Smulski CR, Kury P, Seidel LM, Staiger HS, Edinger AK, Willen L, Seidl M, Hess H, Salzer U, Rolink AG, Rizzi M, Schneider P, Eibel H. BAFF- and TACI-Dependent Processing of BAFFR by ADAM Proteases Regulates the Survival of B Cells. Cell Reports 2017;18:2189-202. [DOI: 10.1016/j.celrep.2017.02.005] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 10.0] [Reference Citation Analysis]
176 Bakshi J, Ismajli M, Rahman A. New therapeutic avenues in SLE. Best Pract Res Clin Rheumatol 2015;29:794-809. [PMID: 27107514 DOI: 10.1016/j.berh.2016.02.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
177 Jiang Y, Cheng L, Li X, Zhou W, Zhang L. Associations between TNFSF4, TNFSF8 and TNFSF15 and Behçet's disease but not VKH syndrome in Han Chinese. Oncotarget 2017;8:105037-46. [PMID: 29285231 DOI: 10.18632/oncotarget.22064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
178 Marín-rosales M, Cruz A, Salazar-camarena DC, Santillán-lópez E, Espinoza-garcía N, Muñoz-valle JF, Ramírez-dueñas MG, Oregón-romero E, Orozco-barocio G, Palafox-sánchez CA. High BAFF expression associated with active disease in systemic lupus erythematosus and relationship with rs9514828C>T polymorphism in TNFSF13B gene. Clin Exp Med 2019;19:183-90. [DOI: 10.1007/s10238-019-00549-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
179 Gomez IG, Roach AM, Nakagawa N, Amatucci A, Johnson BG, Dunn K, Kelly MC, Karaca G, Zheng TS, Szak S, Peppiatt-Wildman CM, Burkly LC, Duffield JS. TWEAK-Fn14 Signaling Activates Myofibroblasts to Drive Progression of Fibrotic Kidney Disease. J Am Soc Nephrol 2016;27:3639-52. [PMID: 27026366 DOI: 10.1681/ASN.2015111227] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
180 Andreou NP, Legaki E, Dovrolis N, Boyanov N, Georgiou K, Gkouskou K, Gazouli M. B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment. Dig Liver Dis 2021;53:574-80. [PMID: 33339749 DOI: 10.1016/j.dld.2020.11.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Davis LS, Reimold AM. Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56:i100-i113. [PMID: 28375452 DOI: 10.1093/rheumatology/kew417] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
182 Morand EF, Leech MT. Successes, challenges and developments in Australian rheumatology. Nat Rev Rheumatol 2015;11:430-6. [PMID: 25756549 DOI: 10.1038/nrrheum.2015.22] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
183 Apostolopoulos D, Morand EF. It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford) 2017;56:i114-22. [PMID: 28013208 DOI: 10.1093/rheumatology/kew406] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
184 Baert L, Ahmed MC, Manfroi B, Huard B. The number 13 of the family: a proliferation inducing ligand. Curr Opin Immunol 2021;71:132-7. [PMID: 34411773 DOI: 10.1016/j.coi.2021.06.018] [Reference Citation Analysis]
185 Lee YH, Song GG. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials. Lupus 2018;27:112-9. [PMID: 28592201 DOI: 10.1177/0961203317713143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
186 Bird AK, Chang M, Barnard J, Goldman BI, Meednu N, Rangel-Moreno J, Anolik JH. Neutrophils Slow Disease Progression in Murine Lupus via Modulation of Autoreactive Germinal Centers. J Immunol 2017;199:458-66. [PMID: 28584005 DOI: 10.4049/jimmunol.1700354] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
187 Goobie GC, Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies in systemic lupus erythematosus: a 2015 update. Curr Opin Rheumatol 2015;27:454-60. [PMID: 26125105 DOI: 10.1097/BOR.0000000000000202] [Cited by in Crossref: 45] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
188 Acosta-Herrera M, González-Serna D, Martín J. The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis. J Clin Med 2019;8:E826. [PMID: 31185701 DOI: 10.3390/jcm8060826] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
189 Zhang Y, Li J, Zhou N, Zhang Y, Wu M, Xu J, Shen C, An X, Shen G, Yang M, Zhang C, Tao J. The Unknown Aspect of BAFF: Inducing IL-35 Production by a CD5+CD1dhiFcγRIIbhi Regulatory B-Cell Subset in Lupus. Journal of Investigative Dermatology 2017;137:2532-43. [DOI: 10.1016/j.jid.2017.07.843] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
190 Kaegi C, Steiner UC, Wuest B, Crowley C, Boyman O. Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders. Allergy 2021;76:2673-83. [PMID: 33368349 DOI: 10.1111/all.14704] [Reference Citation Analysis]
191 Gallagher S, Yusuf I, McCaughtry TM, Turman S, Sun H, Kolbeck R, Herbst R, Wang Y. MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19. Arthritis Rheumatol 2016;68:965-76. [PMID: 26606525 DOI: 10.1002/art.39503] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
192 Appleton BD, Major AS. The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy. Curr Opin Rheumatol 2021;33:211-8. [PMID: 33394753 DOI: 10.1097/BOR.0000000000000773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
193 Dong G, You M, Fan H, Ding L, Sun L, Hou Y. STS-1 promotes IFN-α induced autophagy by activating the JAK1-STAT1 signaling pathway in B cells. Eur J Immunol 2015;45:2377-88. [PMID: 25959715 DOI: 10.1002/eji.201445349] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
194 Tsiantoulas D, Sage AP, Mallat Z, Binder CJ. Targeting B cells in atherosclerosis: closing the gap from bench to bedside. Arterioscler Thromb Vasc Biol 2015;35:296-302. [PMID: 25359862 DOI: 10.1161/ATVBAHA.114.303569] [Cited by in Crossref: 61] [Cited by in F6Publishing: 36] [Article Influence: 8.7] [Reference Citation Analysis]
195 Irure-Ventura J, San Segundo D, Rodrigo E, Merino D, Belmar-Vega L, Ruiz San Millán JC, Valero R, Benito A, López-Hoyos M. High Pretransplant BAFF Levels and B-cell Subset Polarized towards a Memory Phenotype as Predictive Biomarkers for Antibody-Mediated Rejection. Int J Mol Sci 2020;21:E779. [PMID: 31991734 DOI: 10.3390/ijms21030779] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
196 Kowalczyk-Quintas C, Chevalley D, Willen L, Jandus C, Vigolo M, Schneider P. Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab. Front Immunol 2018;9:2698. [PMID: 30524439 DOI: 10.3389/fimmu.2018.02698] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
197 Lenert A, Lenert P. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents. Drug Des Devel Ther 2015;9:333-47. [PMID: 25609919 DOI: 10.2147/DDDT.S67264] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
198 Simonetta F, Allali D, Roux-Lombard P, Chizzolini C. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab. Joint Bone Spine 2017;84:235-6. [PMID: 27238199 DOI: 10.1016/j.jbspin.2016.01.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
199 Hao YF, Bi H, Li HY, Yin LM, Yu JX, Tao W, Mu HL, Yang RC, Zhou ZP, Tai WL. Aberrant Expression of a Proliferation-Inducing Ligand Underlies Autoimmune Mechanisms in Immune Thrombocytopenia. J Immunol Res 2021;2021:3676942. [PMID: 33564689 DOI: 10.1155/2021/3676942] [Reference Citation Analysis]
200 Favoino E, Prete M, Marzullo A, Millo E, Shoenfeld Y, Perosa F. CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases. Clinic Rev Allerg Immunol 2017;52:217-33. [DOI: 10.1007/s12016-016-8551-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
201 Vadori M, Cozzi E. The immunological barriers to xenotransplantation. Tissue Antigens 2015;86:239-53. [PMID: 26381044 DOI: 10.1111/tan.12669] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
202 Xu H, Dong P, Ma X, Song D, Xue D, Xu R, Lu H, He X. B cell-activating factor regulates the survival of B lymphocytes infected with human cytomegalovirus. Immunology Letters 2017;187:1-6. [DOI: 10.1016/j.imlet.2017.04.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
203 Suso JP, Posso-Osorio I, Jiménez CA, Naranjo-Escobar J, Ospina FE, Sánchez A, Cañas CA, Tobón GJ. Profile of BAFF and its receptors' expression in lupus nephritis is associated with pathological classes. Lupus 2018;27:708-15. [PMID: 29087261 DOI: 10.1177/0961203317739132] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
204 Dulak-Lis M, Bujak A, Gala K, Banach M, Kędzierska U, Miszkiel J, Hucz-Kalitowska J, Mroczkiewicz M, Stypik B, Szymczak K, Gunerka P, Dubiel K, Zygmunt BM, Wieczorek M, Pieczykolan JS. A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus. J Pharmacol Sci 2021;145:340-8. [PMID: 33712286 DOI: 10.1016/j.jphs.2021.02.002] [Reference Citation Analysis]
205 Scheinberg M, de Melo FFN, Bueno AN, Costa CM, de Azevedo Bahr MLA, Reis ER. Belimumab for the treatment of corticosteroid-dependent systemic lupus erythematosus: from clinical trials to real-life experience after 1 year of use in 48 Brazilian patients. Clin Rheumatol 2016;35:1719-23. [DOI: 10.1007/s10067-016-3268-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
206 Nasonov EL. [New directions of pharmacotherapy of immune - inflammatory rheumatic diseases]. Ter Arkh 2019;91:98-107. [PMID: 32598760 DOI: 10.26442/00403660.2019.08.000406] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
207 Zhao C, Wang P, Mao Y, Dan Y, Wu Q, Li X, Wang D, Davis C, Hu W, Pan H. Potential role of melatonin in autoimmune diseases. Cytokine & Growth Factor Reviews 2019;48:1-10. [DOI: 10.1016/j.cytogfr.2019.07.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
208 Mackern-Oberti JP, Jara EL, Riedel CA, Kalergis AM. Hormonal Modulation of Dendritic Cells Differentiation, Maturation and Function: Implications for the Initiation and Progress of Systemic Autoimmunity. Arch Immunol Ther Exp (Warsz) 2017;65:123-36. [PMID: 27585815 DOI: 10.1007/s00005-016-0418-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]